Trevi Therapeutics, Inc. $TRVI Shares Acquired by Jump Financial LLC

Key Points

• Jump Financial LLC increased its stake in Trevi Therapeutics by 644.9% in the first quarter, now owning 160,815 shares valued at approximately $1,012,000.
• Trevi Therapeutics reported a quarterly earnings per share of ($0.09), which surpassed analysts' expectations by $0.01, with forecasts predicting an annual EPS of -0.49.
• Several analysts issued positive ratings on Trevi Therapeutics, with price targets ranging from $18.00 to $25.00, and an average target price of $20.11.

Jump Financial LLC lifted its position in shares of Trevi Therapeutics, Inc. (NASDAQ:TRVI - Free Report) by 644.9% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 160,815 shares of the company's stock after acquiring an additional 139,226 shares during the quarter. Jump Financial LLC owned 0.16% of Trevi Therapeutics worth $1,012,000 at the end of the most recent quarter.

Several other institutional investors have also modified their holdings of the company. Wellington Management Group LLP purchased a new stake in shares of Trevi Therapeutics during the 1st quarter worth approximately $802,000. Raymond James Financial Inc. lifted its stake in Trevi Therapeutics by 4,144.8% in the 1st quarter. Raymond James Financial Inc. now owns 509,379 shares of the company's stock valued at $3,204,000 after buying an additional 497,379 shares in the last quarter. American Century Companies Inc. lifted its stake in Trevi Therapeutics by 2.1% in the 1st quarter. American Century Companies Inc. now owns 79,796 shares of the company's stock valued at $502,000 after buying an additional 1,653 shares in the last quarter. Tejara Capital Ltd lifted its stake in Trevi Therapeutics by 16.8% in the 1st quarter. Tejara Capital Ltd now owns 179,516 shares of the company's stock valued at $1,129,000 after buying an additional 25,777 shares in the last quarter. Finally, Persistent Asset Partners Ltd purchased a new stake in Trevi Therapeutics in the 1st quarter valued at approximately $260,000. Hedge funds and other institutional investors own 95.76% of the company's stock.

Wall Street Analyst Weigh In

TRVI has been the topic of a number of recent research reports. D. Boral Capital reaffirmed a "buy" rating and issued a $21.00 target price on shares of Trevi Therapeutics in a research note on Monday, June 2nd. Morgan Stanley initiated coverage on Trevi Therapeutics in a research note on Thursday, August 21st. They issued an "overweight" rating and a $18.00 target price on the stock. Raymond James Financial reduced their target price on Trevi Therapeutics from $29.00 to $27.00 and set a "strong-buy" rating on the stock in a research note on Friday, August 8th. Needham & Company LLC reduced their target price on Trevi Therapeutics from $24.00 to $22.00 and set a "buy" rating on the stock in a research note on Friday, August 8th. Finally, HC Wainwright started coverage on Trevi Therapeutics in a research note on Wednesday, May 28th. They issued a "buy" rating and a $21.00 target price on the stock. Two investment analysts have rated the stock with a Strong Buy rating and eight have issued a Buy rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of "Buy" and a consensus price target of $20.11.

Trevi Therapeutics Price Performance

TRVI traded up $0.08 during trading on Thursday, hitting $7.23. The company's stock had a trading volume of 1,953,144 shares, compared to its average volume of 1,901,081. The firm's 50 day moving average price is $7.04 and its 200-day moving average price is $6.36. The stock has a market cap of $880.47 million, a PE ratio of -17.21 and a beta of 0.71. Trevi Therapeutics, Inc. has a twelve month low of $2.36 and a twelve month high of $8.78.

Trevi Therapeutics (NASDAQ:TRVI - Get Free Report) last issued its quarterly earnings results on Thursday, August 7th. The company reported ($0.09) earnings per share for the quarter, beating the consensus estimate of ($0.10) by $0.01. Equities analysts anticipate that Trevi Therapeutics, Inc. will post -0.49 earnings per share for the current year.

About Trevi Therapeutics

Trevi Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapy Haduvio for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC) conditions targeting the central and peripheral nervous systems.